Publications by authors named "O Boyman"
Article Synopsis
- Low-dose interleukin-2 (IL-2) immunotherapy shows promise for autoimmune diseases by stimulating regulatory T (Treg) cells, particularly in systemic lupus erythematosus (SLE) patients.
- A clinical trial revealed that low-dose IL-2 activates various immune cells, notably Treg cells with skin-homing capabilities, which interact with skin endothelial cells.
- Comprehensive analysis uncovered different subsets of Treg cells influenced by IL-2, indicating targetable immune responses in the treatment of SLE.
The key role of T cells in cancer immunotherapy is well established and is highlighted by the remarkable capacity of Ab-mediated checkpoint blockade to overcome T-cell exhaustion and amplify anti-tumor responses. However, total or partial tumor remission following checkpoint blockade is still limited to only a few types of tumors. Hence, concerted attempts are being made to devise new methods for improving tumor immunity.
View Article and Find Full Text PDFLong Covid is a debilitating condition of unknown etiology. We performed multimodal proteomics analyses of blood serum from COVID-19 patients followed up to 12 months after confirmed severe acute respiratory syndrome coronavirus 2 infection. Analysis of >6500 proteins in 268 longitudinal samples revealed dysregulated activation of the complement system, an innate immune protection and homeostasis mechanism, in individuals experiencing Long Covid.
View Article and Find Full Text PDF